Please use this identifier to cite or link to this item: https://islhd.intersearch.com.au/islhdjspui/handle/1/5534
Title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre
open-label
global
phase 3
randomised
controlled trial
Authors: Sezer A
Kilickap S
Gümüş M
Bondarenko I
Özgüroğlu M
Gogishvili M
Turk HM
Cicin I
Bentsion D
Gladkov O
Clingan P
Sriuranpong V
Rizvi N
Gao B
Li S
Lee S
McGuire K
Chen CI
Makharadze T
Paydas S
Nechaeva M
Seebach F
Weinreich DM
Yancopoulos GD
Gullo G
Lowy I
Rietschel P.
ISLHD Author: Clingan, Philip
Keywords: Pharmagology;Oncology
Date Published: 14-Feb-2021
Citation: Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2.
Keywords: Pharmagology
Oncology
URI: https://islhd.intersearch.com.au/islhdjspui/handle/1/5534
Appears in Collections:Research publications from current and former ISLHD staff.

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.